IS8447A - Aðferð til að framleiða gamma-karboxýleruð prótín - Google Patents

Aðferð til að framleiða gamma-karboxýleruð prótín

Info

Publication number
IS8447A
IS8447A IS8447A IS8447A IS8447A IS 8447 A IS8447 A IS 8447A IS 8447 A IS8447 A IS 8447A IS 8447 A IS8447 A IS 8447A IS 8447 A IS8447 A IS 8447A
Authority
IS
Iceland
Prior art keywords
producing gamma
carboxylated protein
carboxylated
protein
gamma
Prior art date
Application number
IS8447A
Other languages
English (en)
Inventor
Fenge Christel
Lövgren Ann
Thelin Anders
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29559260&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS8447(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS8447A publication Critical patent/IS8447A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
IS8447A 2003-10-14 2006-05-10 Aðferð til að framleiða gamma-karboxýleruð prótín IS8447A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0324044.7A GB0324044D0 (en) 2003-10-14 2003-10-14 Protein
PCT/SE2004/001453 WO2005038019A1 (en) 2003-10-14 2004-10-12 Method for producing gamma-carboxylated proteins

Publications (1)

Publication Number Publication Date
IS8447A true IS8447A (is) 2006-05-10

Family

ID=29559260

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8447A IS8447A (is) 2003-10-14 2006-05-10 Aðferð til að framleiða gamma-karboxýleruð prótín

Country Status (28)

Country Link
US (2) US7842477B2 (is)
EP (2) EP2292748B1 (is)
JP (1) JP4658946B2 (is)
KR (1) KR101201020B1 (is)
CN (2) CN102443548B (is)
AR (1) AR046180A1 (is)
AT (1) ATE491789T1 (is)
AU (2) AU2004281350B2 (is)
BR (1) BRPI0415277A (is)
CA (1) CA2541764C (is)
CO (1) CO5690657A2 (is)
DE (1) DE602004030603D1 (is)
DK (1) DK1678297T3 (is)
ES (2) ES2357603T3 (is)
GB (1) GB0324044D0 (is)
IL (2) IL174633A (is)
IS (1) IS8447A (is)
MX (1) MXPA06004060A (is)
MY (1) MY141859A (is)
NO (1) NO339740B1 (is)
NZ (2) NZ546584A (is)
PL (1) PL1678297T3 (is)
PT (1) PT1678297E (is)
RU (2) RU2372401C2 (is)
TW (1) TWI355419B (is)
UY (1) UY28558A1 (is)
WO (1) WO2005038019A1 (is)
ZA (1) ZA200603038B (is)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2380985E (pt) * 2003-09-23 2014-03-26 Univ North Carolina Células que expressam a vitamina k epóxido reductase e sua utilização
GB0324044D0 (en) 2003-10-14 2003-11-19 Astrazeneca Ab Protein
CA2601574C (en) * 2005-03-15 2014-12-02 University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
WO2006110083A1 (en) 2005-04-13 2006-10-19 Astrazeneca Ab A host cell comprising a vector for production of proteins requiring gamma-carboxylation
AU2006298160A1 (en) * 2005-09-30 2007-04-12 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Process for preparing recombinant human thrombin with culture cell
US7745484B2 (en) 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
PL1969127T5 (pl) * 2005-12-21 2018-02-28 Cnj Holdings, Inc Metoda wytwarzania biologicznie czynnych białek zależnych od witaminy K metodami rekombinacji
EP1996186A4 (en) * 2006-03-06 2009-07-22 Humagene Inc PROCESS FOR THE PREPARATION OF RECOMBINANT HUMAN THROMBIN AND FIBRINOGEN
CA2683423C (en) * 2007-04-26 2020-10-27 Inspiration Biopharmaceuticals, Inc. Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
US8206967B2 (en) * 2007-07-06 2012-06-26 Medimmune Limited Method for production of recombinant human thrombin
MX343784B (es) 2010-10-06 2016-11-23 Medimmune Ltd Factor ii y fibrinogeno para tratamiento de trastornos hemostaticos.
EP2655607A4 (en) 2010-12-21 2014-05-14 Univ North Carolina METHOD AND COMPOSITIONS FOR PRODUCING ACTIVE VITAMIN K-DEPENDENT PROTEINS
CA2847818A1 (en) * 2011-09-06 2013-03-14 Medimmune, Llc Methods for processing coagulation factors
RU2500816C1 (ru) * 2012-07-19 2013-12-10 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК рАК380, КОДИРУЮЩАЯ ПОЛИПЕПТИД РЕКОМБИНАНТНОГО ФАКТОРА IХ СВЕРТЫВАЕМОСТИ КРОВИ ЧЕЛОВЕКА, ЛИНИЯ КЛЕТОК Cricetulus griseus CHO 1E6 - ПРОДУЦЕНТ РЕКОМБИНАНТНОГО ФАКТОРА IХ СВЕРТЫВАЕМОСТИ КРОВИ ЧЕЛОВЕКА И СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА, ОБЛАДАЮЩЕГО АКТИВНОСТЬЮ РЕКОМБИНАНТНОГО ФАКТОРА IХ
JP5830486B2 (ja) 2013-03-29 2015-12-09 シスメックス株式会社 組換えバキュロウイルスおよびその利用
SG11201604218RA (en) * 2013-12-20 2016-07-28 Novartis Ag Novel eukaryotic cells and methods for recombinantly expressing a product of interest
CN109207462B (zh) * 2018-08-01 2021-05-11 深圳市新产业生物医学工程股份有限公司 异常凝血酶原及其制备方法和包含其的检测剂、试剂盒及应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3043857A1 (de) 1980-11-21 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ii und vii
US4599308A (en) * 1981-10-06 1986-07-08 Hamer Dean H Protein from SV40 recombinants
DE3584341D1 (de) * 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
ZA862768B (en) * 1985-04-17 1986-12-30 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
JPH01502080A (ja) 1986-11-17 1989-07-27 ニュー・イングランド・メディカル・センター 組み換えビタミンｋ依存性蛋白質のガンマカルボキシル化の増強
US6224864B1 (en) * 1986-12-03 2001-05-01 Pharmacia & Upjohn Company Antibiotic 10381A, and process for the preparation of anitbiotics 10381B
EP0380508A4 (en) 1987-05-18 1991-04-03 Integrated Genetics, Inc. Improved protein c molecules and method for making and activating same
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
US5118614A (en) * 1988-01-18 1992-06-02 Tessek Sdruzeni Praha Concentrates of coagulation factors ii, vii, ix and x, method of their preparation and use
EP0540650A1 (en) 1990-07-23 1993-05-12 Zymogenetics, Inc. Gamma-carboxylase and methods of use
WO1998035689A1 (en) * 1997-02-14 1998-08-20 American Red Cross Expression of active human factor ix in mammary tissue of transgenic animals
US5965789A (en) 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
US5268275A (en) 1991-05-08 1993-12-07 The University Of North Carolina At Chapel Hill Vitamin K-dependent carboxylase
US5219995A (en) 1992-07-14 1993-06-15 Alpha Therapeutic Corporation Plasma fraction purification
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5639661A (en) * 1994-03-23 1997-06-17 The University Of Iowa Research Foundation Genes and proteins for treating cystic fibrosis
DE4430204A1 (de) 1994-08-26 1996-02-29 Behringwerke Ag Arzneimittel, welches als Gegenmittel für Blut-Antikoagulanzien geeignet ist und seine Verwendung
HUP9700603A3 (en) * 1996-03-20 2001-08-28 Baxter Ag Pharmaceutical preparation for the treatment of blood coagulation disorders
JP2002500011A (ja) 1997-12-24 2002-01-08 イミュネックス・コーポレーション Ｖ２０１ｄｎａ及びポリペプチド
US6413737B1 (en) * 1999-07-09 2002-07-02 Cohesion Technologies, Inc. Ecarin prothrombin protease and methods
AU6366100A (en) 1999-07-23 2001-02-13 Case Western Reserve University Novel methods and reagents for the treatment of osteoarthritis
AU2001268373A1 (en) * 2000-06-13 2001-12-24 The Children's Hospital Of Philadelphia Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus
EP1325127B1 (en) 2000-10-02 2009-03-11 Novo Nordisk Health Care AG Method for the production of vitamin k-dependent proteins
WO2003004641A1 (en) 2001-07-06 2003-01-16 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Process for producing human thrombin by gene modification technique
KR101054735B1 (ko) 2001-07-06 2011-08-05 잇판자이단호진 가가쿠오요비겟세이료호겐쿠쇼 유전자 재조합 에카린 및 그를 제조하는 방법
WO2003006054A1 (en) 2001-07-10 2003-01-23 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Pharmaceutically stable hemostatic compositions
PT2380985E (pt) * 2003-09-23 2014-03-26 Univ North Carolina Células que expressam a vitamina k epóxido reductase e sua utilização
DK2189523T3 (da) 2003-10-14 2012-03-12 Baxter Int VKORC1 (vitamin K-epoxid-tilbageføringspolypeptid), et terapeutisk mål for coumarin og dets derivater
GB0324044D0 (en) 2003-10-14 2003-11-19 Astrazeneca Ab Protein
EP2180045B1 (en) 2003-10-24 2015-12-23 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Novel protein highly producing recombinant animal cell, method for preparing the same and method for mass-producing protein using the same
EP1831363A1 (en) 2004-12-21 2007-09-12 Novo Nordisk Health Care AG Expression of gamma-carboxylated polypeptides in gamma-carboxylation deficient host systems
WO2006110083A1 (en) * 2005-04-13 2006-10-19 Astrazeneca Ab A host cell comprising a vector for production of proteins requiring gamma-carboxylation
ATE486128T1 (de) 2005-12-02 2010-11-15 Univ Wake Forest Health Sciences Zusammensetzungen und verfahren zur erhöhung der produktion rekombinanter gamma-carboxylierter proteine
PL1969127T5 (pl) * 2005-12-21 2018-02-28 Cnj Holdings, Inc Metoda wytwarzania biologicznie czynnych białek zależnych od witaminy K metodami rekombinacji
US8206967B2 (en) * 2007-07-06 2012-06-26 Medimmune Limited Method for production of recombinant human thrombin

Also Published As

Publication number Publication date
RU2009123931A (ru) 2010-12-27
TW200523365A (en) 2005-07-16
ES2532470T3 (es) 2015-03-27
MY141859A (en) 2010-07-16
IL174633A (en) 2013-06-27
GB0324044D0 (en) 2003-11-19
EP2292748A1 (en) 2011-03-09
PT1678297E (pt) 2011-03-15
NO20061470L (no) 2006-05-12
CN102443548B (zh) 2014-03-12
PL1678297T3 (pl) 2011-11-30
AU2004281350A1 (en) 2005-04-28
JP4658946B2 (ja) 2011-03-23
CN102443548A (zh) 2012-05-09
ES2357603T3 (es) 2011-04-28
NO339740B1 (no) 2017-01-30
RU2372401C2 (ru) 2009-11-10
US7842477B2 (en) 2010-11-30
CA2541764C (en) 2015-03-31
CO5690657A2 (es) 2006-10-31
US20110092429A1 (en) 2011-04-21
JP2007508820A (ja) 2007-04-12
AU2004281350B2 (en) 2008-05-15
DK1678297T3 (da) 2011-03-14
AR046180A1 (es) 2005-11-30
NZ546584A (en) 2009-08-28
KR101201020B1 (ko) 2012-11-14
CN1867669B (zh) 2011-10-19
TWI355419B (en) 2012-01-01
IL174633A0 (en) 2006-08-20
DE602004030603D1 (de) 2011-01-27
IL226313A0 (en) 2013-06-27
AU2008205445A1 (en) 2008-09-04
CN1867669A (zh) 2006-11-22
MXPA06004060A (es) 2006-06-28
CA2541764A1 (en) 2005-04-28
BRPI0415277A (pt) 2006-12-19
NZ578306A (en) 2011-02-25
US20050164367A1 (en) 2005-07-28
EP1678297B1 (en) 2010-12-15
ZA200603038B (en) 2007-09-26
US8697440B2 (en) 2014-04-15
ATE491789T1 (de) 2011-01-15
HK1155475A1 (en) 2012-05-18
KR20060123152A (ko) 2006-12-01
EP1678297A1 (en) 2006-07-12
WO2005038019A1 (en) 2005-04-28
EP2292748B1 (en) 2014-12-17
RU2006110147A (ru) 2007-11-20
UY28558A1 (es) 2005-05-31

Similar Documents

Publication Publication Date Title
CY2015015I1 (el) Παραγωγη τιακουμυκινης
DK1687066T3 (da) Fremgangsmåder til immunmodulering
PT1398327E (pt) Método de produção de derivados de hidroxialquil-amido
DE60205413D1 (de) Herstellungsverfahren
EE200300420A (et) Vormitiste tootmise meetod
IS8122A (is) Aðferð til að framleiða N-útskipt 2-sýanópýrrólídín
IL174633A0 (en) Method for producing gamma-carboxylated proteins
PL394821A1 (pl) Sposób wytwarzania kombrestatyn
DK1691787T3 (da) Fremgangsmåde til at danne småpartikler
NO20041150L (no) Fremgangsmate for a danne en sammenfoyning.
IS8416A (is) Aðferð við framleiðslu á CCR-2 mótlyfi
IS7069A (is) Aðferð til að framleiða zaleplon
IS7981A (is) Aðferð til að framleiða örkerfi
DE602004003115D1 (de) Tonerherstellungsverfahren
NO20035626D0 (no) Metode
IS8333A (is) Aðferð við framleiðslu á THIP
NO20035401D0 (no) Metode
IS7339A (is) Aðferð til framleiðslu á 7alfa-metýlsterum
NO20054532D0 (no) Fremgangsmater for a forhindre glukonoylering av proteiner
ITMI20021432A0 (it) Metodo per produrre cefalosporine
EP1760149A4 (en) PROCESS FOR CONSTRUCTING MODIFIED PROTEIN
IS6928A (is) Aðferðir til að framleiða mirtasapínmilliefni
NO20035692D0 (no) Produksjonsmetode
ITTO20030359A1 (it) Metodo di produzione di focacce farcite.
PL359838A1 (pl) Sposób wytwarzania nano-ścieżek